Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jun 30;14(6):2353-2358.
doi: 10.21037/tlcr-2025-694. Epub 2025 Jun 26.

Long-term efficacy and improved overall survival of lorlatinib in anaplastic lymphoma kinase-rearranged lung cancer: is cure a dream or a reality?

Yoshitsugu Horio  1   2 , Hiroaki Kuroda  3 , Eiichi Sasaki  4 , Katsuhiro Masago  4
Affiliations
Editorial

Long-term efficacy and improved overall survival of lorlatinib in anaplastic lymphoma kinase-rearranged lung cancer: is cure a dream or a reality?

Yoshitsugu Horio et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Non-small cell lung cancer (NSCLC); anaplastic lymphoma kinase-rearrangement (ALK-rearrangement); lorlatinib; tyrosine kinase inhibitor (TKI).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2025-694/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Voena C, Ambrogio C, Iannelli F, et al. ALK in cancer: from function to therapeutic targeting. Nat Rev Cancer 2025;25:359-78. 10.1038/s41568-025-00797-9 - DOI - PMC - PubMed
    1. Lin JJ, Horan JC, Tangpeerachaikul A, et al. NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Cancer Discov 2024;14:2367-86. 10.1158/2159-8290.CD-24-0231 - DOI - PMC - PubMed
    1. Lee ATM, Ou SI. Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver. Lung Cancer (Auckl) 2024;15:19-27. - PMC - PubMed
    1. Ou SI, Solomon BJ, Besse B, et al. Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report. J Thorac Oncol 2025;20:513-20. 10.1016/j.jtho.2024.11.021 - DOI - PubMed
    1. Ou SI, Lee ATM, Nagasaka M. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC. Crit Rev Oncol Hematol 2023;187:104019. 10.1016/j.critrevonc.2023.104019 - DOI - PubMed